February 21, 2007 – InSightec’s ExAblate 2000, a Magnetic Resonance Imaging (MRI) focused ultrasound device that treats uterine fibroid tumors, is now allowing most patients to find relief within three months of treatment and to return to work within days.
The ExAblate 2000 uses a combination of ultrasound waves and MRIs to image, treat and ablate soft tissue. Treatment typically takes about three or four hours.
Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...
March 09, 2026 
March 5, 2026 — At the Health Information and Management Systems Society (HIMSS) Conference & Exhibition 2026 in Las ...
March 06, 2026 
March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...
March 03, 2026 
March 2, 2026 — Ultrasound AI, a provider of artificial intelligence applications for medical imaging, has received FDA ...
March 03, 2026 
March 3, 2026 — MedDream will present its cloud-native, AI-ready universal DICOM viewer in the Amazon Web Services (AWS) ...
March 03, 2026 
Feb. 26, 2026 — AS Software, a provider of specialty-focused ultrasound reporting solutions, has announced that the U.S ...
March 02, 2026 
Feb. 26, 2026 — GE HealthCare and UCSF Health have announced a 10-year Care Alliance collaboration focused on ...
March 02, 2026 
Feb. 26, 2026 — DeepHealth, Inc., a provider of AI-powered health informatics and a wholly owned subsidiary of RadNet ...
February 27, 2026 
Feb. 23, 2026 — Bracco, a global leader in diagnostic imaging, recently announced that the U.S. Food and Drug ...
February 24, 2026 
Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...
February 13, 2026 